Vinge has advised the biopharmaceutical development company Cinclus Pharma in connection with a private placement of approximately SEK 240 million by way of a directed share issue to several new investors and current shareholders.
The purpose of the share issue is to fund the further clinical development of linaprazan glurate, a clinical-stage drug candidate for the treatment of gastroesophageal reflux disease (GERD), accelerate the Company’s commercialization strategy and broaden the shareholder base.
Vinge’s team consisted primarily of Dain Hård Nevonen, Amanda Knutsson, Stojan Arnerstål, Maria Schultzberg and Anna Svensson.
